0RQJ Stock Chart & Stats
kr21.15
kr0.05(0.69%)
At close: 4:00 PM EST
kr21.15
kr0.05(0.69%)
Day’s Range― - ―
52-Week Rangekr8.66 - kr28.15
Previous CloseN/A
Volume372.00
Average Volume (3M)7.00K
Market Cap
kr1.32B
Enterprise Valuekr1.32B
Total Cash (Recent Filing)kr486.31M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)7.1
Beta1.01
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding138,030,140
10 Day Avg. Volume2,333
30 Day Avg. Volume7,002
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr267.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetZero debt and TTM equity of about 548M against 601M of assets provide a conservative funding base. This reduces balance-sheet strain and preserves flexibility to finance pipeline development or withstand uneven biotech cash flows over the next several quarters.
Positive Cash GenerationPositive operating cash flow and free cash flow in 2024, 2025, and TTM indicate that recent operations have generated cash rather than consuming it. This supports continued R&D execution and reduces immediate reliance on external financing, although cash conversion varies.
Sharp Profitability ImprovementProfitability improved dramatically from heavy losses in 2021–2023, reaching roughly 51% TTM net margin and 55% EBIT margin. This earnings inflection could strengthen internally funded development and improve Saniona’s position when negotiating future partnerships.
Bears Say
Extreme Revenue VolatilityLatest TTM revenue growth was -110% after surges in 2024–2025, showing that reported revenue can reverse sharply. For a licensing- and milestone-driven biotech, this volatility weakens visibility into recurring growth and makes current earnings power harder to underwrite.
Uneven Cash ConversionTTM free cash flow was about 70% of net income, while annual free-cash-flow growth fell in 2025 before rebounding sharply in TTM. This uneven conversion makes internally generated funding less predictable and can complicate sustained pipeline investment.
Historical Capital Structure InstabilityAlthough the balance sheet is now debt-free, equity was negative in 2023 after leverage in 2022, and returns and equity have been volatile. That history indicates the current capital structure has not yet demonstrated stability through the full development cycle.
Saniona AB News
0RQJ FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest share price was kr8.66 and its highest was kr28.15 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.32B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Nov 26, 2026 which is in 44 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Aug 27, 2026. The company reported -kr0.422 earnings per share for the quarter.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.422 in its last earnings report. Following the earnings report the stock price went up 0.932%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in GB:0RQJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
Camurus AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―